DK1596868T3 - Fremgangsmåde til behandling af hjertesvigt og medikament dertil - Google Patents

Fremgangsmåde til behandling af hjertesvigt og medikament dertil

Info

Publication number
DK1596868T3
DK1596868T3 DK04713672T DK04713672T DK1596868T3 DK 1596868 T3 DK1596868 T3 DK 1596868T3 DK 04713672 T DK04713672 T DK 04713672T DK 04713672 T DK04713672 T DK 04713672T DK 1596868 T3 DK1596868 T3 DK 1596868T3
Authority
DK
Denmark
Prior art keywords
drug
heart failure
treating heart
treating
failure
Prior art date
Application number
DK04713672T
Other languages
Danish (da)
English (en)
Inventor
Osamu Sato
Atsushi Ozaki
Yosuke Maki
Yoshitaka Yamamura
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1596868(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of DK1596868T3 publication Critical patent/DK1596868T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04713672T 2003-02-24 2004-02-23 Fremgangsmåde til behandling af hjertesvigt og medikament dertil DK1596868T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24
PCT/JP2004/002085 WO2004073716A1 (en) 2003-02-24 2004-02-23 Method for treating severe heart failure and medicament therefor

Publications (1)

Publication Number Publication Date
DK1596868T3 true DK1596868T3 (da) 2008-12-08

Family

ID=32908667

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04713672T DK1596868T3 (da) 2003-02-24 2004-02-23 Fremgangsmåde til behandling af hjertesvigt og medikament dertil

Country Status (24)

Country Link
US (2) US7423032B2 (no)
EP (2) EP2000142A1 (no)
JP (2) JP4771937B2 (no)
KR (1) KR100706727B1 (no)
CN (1) CN100577171C (no)
AR (1) AR043259A1 (no)
AT (1) ATE411803T1 (no)
AU (2) AU2004212842B9 (no)
BR (1) BRPI0405657A (no)
CA (1) CA2493475A1 (no)
CY (1) CY1108583T1 (no)
DE (1) DE602004017283D1 (no)
DK (1) DK1596868T3 (no)
ES (1) ES2315640T3 (no)
HK (1) HK1084037A1 (no)
MX (1) MXPA05001623A (no)
MY (1) MY143740A (no)
NO (1) NO335369B1 (no)
PL (2) PL404315A1 (no)
PT (1) PT1596868E (no)
RU (2) RU2346689C2 (no)
SI (1) SI1596868T1 (no)
TW (1) TWI322689B (no)
WO (1) WO2004073716A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US20100004206A1 (en) 2005-12-27 2010-01-07 Makoto Komatsu Water-soluble benzoazepine compound and its pharmaceutical composition
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
DK2146721T3 (da) * 2007-05-15 2013-07-22 Otsuka Pharma Co Ltd Fremgangsmåder til anvendelse af vasopressinantagonister med anthracyclin-kemoterapi-midler til reduktion af kardiotoksicitet og/eller forbedring af overlevelse
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
ES2903231T3 (es) 2008-02-26 2022-03-31 Jenavalve Tech Inc Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente
JP2013526388A (ja) 2010-05-25 2013-06-24 イエナバルブ テクノロジー インク 人工心臓弁、及び人工心臓弁とステントを備える経カテーテル搬送体内プロテーゼ
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
CN105491978A (zh) 2013-08-30 2016-04-13 耶拿阀门科技股份有限公司 用于假体瓣膜的径向可折叠框架及其制造方法
WO2016177562A1 (en) 2015-05-01 2016-11-10 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
JP7081749B2 (ja) 2016-05-13 2022-06-07 イエナバルブ テクノロジー インク 心臓弁プロテーゼ送達システム
CN110392557A (zh) 2017-01-27 2019-10-29 耶拿阀门科技股份有限公司 心脏瓣膜模拟
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5753677A (en) 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
EP0450097B1 (en) 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
WO1994001113A1 (en) 1992-07-02 1994-01-20 Otsuka Pharmaceutical Company, Limited Oxytocin antagonist
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JP3002766B2 (ja) 1994-12-09 2000-01-24 大塚製薬株式会社 脳浮腫治療剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
BR0017074A (pt) 2000-01-26 2002-12-03 Warner Lambert Co Combinações de inibidor de ace-antagonista de vasopressina
US20030008860A1 (en) * 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
ATE367815T1 (de) * 2000-10-04 2007-08-15 Astellas Pharma Inc Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
CN1700919A (zh) 2005-11-23
PL218069B1 (pl) 2014-10-31
MXPA05001623A (es) 2005-04-25
EP1596868A4 (en) 2006-03-29
RU2005102110A (ru) 2005-09-20
EP1596868B1 (en) 2008-10-22
CY1108583T1 (el) 2014-04-09
TW200418489A (en) 2004-10-01
NO20050569D0 (no) 2005-02-02
US7749993B2 (en) 2010-07-06
JP2011148806A (ja) 2011-08-04
RU2346689C2 (ru) 2009-02-20
TWI322689B (en) 2010-04-01
EP2000142A1 (en) 2008-12-10
AR043259A1 (es) 2005-07-20
KR20050105972A (ko) 2005-11-08
DE602004017283D1 (de) 2008-12-04
NO20050569L (no) 2005-11-22
HK1084037A1 (en) 2006-07-21
EP1596868A1 (en) 2005-11-23
BRPI0405657A (pt) 2005-07-19
CN100577171C (zh) 2010-01-06
PL404315A1 (pl) 2013-08-05
US7423032B2 (en) 2008-09-09
AU2004212842B2 (en) 2009-01-08
ES2315640T3 (es) 2009-04-01
AU2004212842A1 (en) 2004-09-02
RU2008133654A (ru) 2010-02-20
WO2004073716A1 (en) 2004-09-02
MY143740A (en) 2011-07-15
US20080214523A1 (en) 2008-09-04
PT1596868E (pt) 2009-01-14
PL373432A1 (en) 2005-08-22
NO335369B1 (no) 2014-12-01
AU2009201109A1 (en) 2009-04-09
US20050187210A1 (en) 2005-08-25
ATE411803T1 (de) 2008-11-15
AU2004212842B9 (en) 2009-03-05
KR100706727B1 (ko) 2007-04-12
CA2493475A1 (en) 2004-09-02
SI1596868T1 (sl) 2008-12-31
JP4771937B2 (ja) 2011-09-14
JP2006518731A (ja) 2006-08-17

Similar Documents

Publication Publication Date Title
DK1596868T3 (da) Fremgangsmåde til behandling af hjertesvigt og medikament dertil
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1673214T3 (da) Apparat og fremgangsmåde til behandling af slam
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK2878297T3 (da) Lægemidler til behandling og forebyggelse af fibrotiske sygdomme
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK1608842T3 (da) System og fremgangsmåde til cementering med omvendt cirkulation
IS7699A (is) Afleiður af díoxan-2-alkýl karbamötum, framleiðslu aðferð þeirra og notkun við meðferð sjúkdóma
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1679058T3 (da) Farmaceutisk sammensætning til behandling af kardiovaskulære og cerebrovaskulære sygdomme
IS8082A (is) Inndælingarbúnaður án nálar og aðferð til inndælingar
DK1539115T3 (da) Fremgangsmåder og doseringsformer til kontrolleret levering af paliperidon
DK3889142T3 (da) 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsense-suppression og behandling af sygdom
NO20053874D0 (no) Formulering og metoder for behandling av thrombocytemi
NO20031053D0 (no) Middel og framgangsmåte for syrebehandling av underjordiske formasjoner
DK1506041T3 (da) Inbandronsyre til behandling og forebyggelse af osteoporose
DK1542710T3 (da) Fremgangsmåde til konservering af organer og væv
DK1611890T3 (da) Fremgangsmåde til evaluering og behandling af cancer
IS7848A (is) Essítalópram hýdróbrómíð og aðferð til framleiðslu þess
DK1919290T3 (da) Fremgangsmåder og produkter til behandling af sygdomme
DK1599469T3 (da) Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed
DK1768489T3 (da) Apparat og fremgangsmåde til destruktion af vegetation
IS7572A (is) Aðferð og efni til lækninga
DK1520587T3 (da) Allergivaccinesammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf til allergibehandling